This month, two Israeli pharmaceutical companies received good news from the US Food and Drug Administration (FDA). Jerusalem’s Gamida Cell was granted orphan product development status for NiCord, its enriched stem-cell treatment for acute lymphoblastic leukemia, acute myeloid leukemia, Hodgkin lymphoma and myelodysplastic syndrome. Orphan drug designation promotes the development of promising...
Continue Reading >>
PA Doubles Pay-To-Slay Salary of Terrorist Behind Murder of Three Israeli Teens
After reports earlier this week that the Palestinian Authority (PA) stepped up its support for the sickening “pay-to-slay” policy by